

**ESPS Peer-review Report**
**Name of Journal:** World Journal of Cardiology

**ESPS Manuscript NO:** 8482

**Title:** The Neuregulin-1/erbB Signaling Activities with focus on the Susceptibility of the Heart to Anthracycline-based Therapeutics

**Reviewer code:** 00234688

**Science editor:** Gou, Su-Xin

**Date sent for review:** 2013-12-28 21:08

**Date reviewed:** 2014-01-06 20:25

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

**COMMENTS TO AUTHORS**

This review examines the NRG1 activities monitored in different model systems, focusing on several biomolecular aspects and deeply analyzing the panel of activities of the NRG1-pathway involved in different physiopathological conditions. A specific point of interest is represented by an attempt to clarify the role of impaired NRG1 in the process of cardiac remodeling related to drugs cardiotoxicity. The review is well written and may represent a reference for experimental purposes in the field.

**ESPS Peer-review Report**
**Name of Journal:** World Journal of Cardiology

**ESPS Manuscript NO:** 8482

**Title:** The Neuregulin-1/erbB Signaling Activities with focus on the Susceptibility of the Heart to Anthracycline-based Therapeutics

**Reviewer code:** 01204088

**Science editor:** Gou, Su-Xin

**Date sent for review:** 2013-12-28 21:08

**Date reviewed:** 2014-01-10 14:58

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

**COMMENTS TO AUTHORS**

Vasti et al. reviewed the panel of activities of the NRG1 pathway, affecting cardiomyocyte survival, proliferation, differentiation and specification, to further focus on molecular pathways synergistically deregulated in experimental condition of an impaired NRG1 signaling and doxorubicin therapy. This review is informative and useful for the readers of the Journal. I just have several comments. Page 22, line 7. What does (14) mean? Style of the reference section should be modified according to the instructions for the authors. The authors should reference some important papers, such as a review by Odiete et al (Circ Res 2012;111:1376-1385.) or a paper by Garcia-Rivello H and Hertig CM (Am J Physiol Heart Circ Physiol 2005;289:H1153-H1160.).